Cancer has become a significant public health concern all over the world. This has created a need for outstanding publications of research and basic science on the oncology and cancer. This is needed not only by those working in cancer research but others who might be interested to know how to fight this illness. Oncotarget plays a significant role in cancer research due to its adherence to ethical guidelines. If you are looking for anything on cancer research, Oncotarget is the best journal to read.
Oncotarget a twice-weekly, open-access and peer-reviewed publication covers a multiplicity of topics on oncology and many other topics such as aging, microbiology, pathology, immunology, and chromosomes. The journal was established in 2010 and has published more than eight volumes and 324 issues since it’s inception. Visit Soundcloud to listen an audio podcast of Oncotarget.
Oncotarget’s mission is to make scientific knowledge and results widely available to eliminate challenges among multiple biomedical disciplines. Oncotarget promotes the application of research in the fight against cancer. It aims to promote a cancer-free society. The critical thing to note is that Oncotarget is mainly a publication by scientists for scientists, to help them as a resource in research.
Realizing after a brief spell of respite that their disease is drug-resistant and therefore incurable is the worst thing that can happen to most people diagnosed with cancer. This is devastating news for those suffering from papillary thyroid carcinoma (PTC) in particula as it is perhaps the most prevalent form of thyroid cancer.
Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/
Oncotarget provides valuable information about the latest research to help these patients. Ordinarily, the vemurafenib drug is used in the treatment of such patients. But recent tests have shown that the FDA-approved drug Palbociclib, are able to treat various forms of disease. Palbociclib also helps them to break down Vemurafenib drug resistance.
Researchers have also found that a combination of Vemurafenib and Palbociclib presents a potent option in the cure of PTC. They do this by working together to generate a stronger force that kills more cells than when the drug was working alone. The researchers also found that the combined therapy also targeted PTC cells while overcoming resistance. Visit Oncotarget’s profile page at facebook.com
The Holidays are a time for giving and sharing, and most people are doing it because of the pleasure that they feel which is popularly known as the “helper’s high” phenomenon. However, it is interesting to note that science does not have a concrete explanation why the phenomenon happens. “Helper’s high” has been described and observed since the ancient times, and there has been a popular proverb regarding the phenomenon, which states that “giving is better than receiving.” Despite the advancement in technology, only a few brave souls tried to navigate the mind and find out why the phenomenon known as “helper’s high” happens. Learn more about Jorge Moll at Google Scholar.
A neuroscientist from Brazil named Jorge Moll teamed up with several neuroscientists around the world. Their goal is to find out the reason why the “helper’s high” phenomenon happens, and for them to study the phenomenon, they need to get volunteers who are willing to be studied. The research happened in 2006, and as Jorge Moll speaks with the volunteers, to explain to them in detailed what is going to happen. He requested that the volunteers should think of a scenario that can happen in reality – the volunteers would have to picture them in a situation wherein they would be generous, and another one wherein they would be selfish. The volunteers had to go inside an empty room for them to concentrate, and as they were thinking about the scenario, equipment near them measures the activity of the brain. Read more about Jorge Moll at crunchbase.com.
Jorge Moll and his team observed the volunteers agree to be studied upon, and after the experiment, they were surprised with the result which came up on screen. It seems like the volunteers’ brain had so much activity when they imagined a scenario of generosity, and nothing happened when they envisioned a scenario of selfishness. This led Jorge Moll and his team to conclude that giving excites a particular part of the brain which causes it to release hormones that are described as more pleasurable than having sex or eating something delicious. Jorge Moll recorded the results of the experiment and stated that there would be follow up studies about their discovery.
An affiliate of Highland Capital Management out of Dallas, Texas out of Korea has closed a private equity fund that was focused on healthcare with capital commitments totaling one-hundred and forty-seven dollars. The fund’s anchor investor is the National Pension Service of South Korea. Valued at an estimated four-hundred and ninety-nine billion dollars at its 1988 interception with a four-hundred and sixty-five billion corpos reported by the Sovereign Wealth Fund Institute. Read more about Highland Capital at prnewswire.com.
There are objectives in addition to return on investments for the investors in the NPS Korea segment of the Highland fund in the area of healthcare. In an effort to severe the strategic objectives in the U.S. China and Korea co-investment opportunity access is included. In Asia the fund will be co-managed by Stonebridge Capital, which is a private venture capital and equity firm.
This will be the first private equity firm focused on healthcare for Highland Capital Management in Asia. The majority of investments have come from multipurpose funds or been made directly though over the last two years an increased amount of interest has been seen in the sector from Asian investors. Highland has a lot of expertise when it comes to healthcare, not only is it the largest industry they are associate with but it makes up over half of the fifteen years of private equity.
Asia and North America’s healthcare companies that are considered to be middle market wil the primary targets for investing. There are several fund structures and classes of assets in the one and a half billion dollars of healthcare assets that Highland Capital has under its management. There are emerging markets, natural resources, short and long term equities offered by Highland. Visit highlandcap.com to know more.
There are people who have come from other lands and found success in the United States. Adam Milstein is one of those people. He is an Israeli-American who made his way to the United States back in 1981. This man is a Managing Partner for Hager Pacific Properties, and he is successful in the work that he is doing. Adam Milstein is someone who sits on the boards of various organizations, and he gives of himself each day. He is someone who is focused on the real estate world and the work that he does there, but he is also someone who is involved in many philanthropic efforts.
Different people become excited about different things, and that helps those people to enjoy the jobs that they do. Adam Milstein is someone who grows excited by watching the world of real estate and all that is going on there. He has said that he gets excited by seeing the various ups and downs that take place in real estate. There are always things that are changing when it comes to real estate and the values of properties, and he enjoys seeing all of those changes as they happen.
There are some who can only live out their lives in the way that they want to if they have very specific goals that they are following after. Adam Milstein is someone who believes that goals can limit a person. He has shared that one of the things that helped him to become as successful as he is was his decision to let go of goals. He does not set specific goals for himself, as he feels that such goals only limit him and stop him from becoming all that he wants to be. Adam Milstein believes that he is better off without specific goals being a part of his life.
Highland Capital is one of the largest global alternative credit managers in the United States. Over the years, Highland Capital has partnered and invested with a variety companies on various projects. It is estimated that the company has approximately $14 billion dollars in assets under their management. It all started in January of 1990. Read this article at investopedia.com. Two men, James Dondero and Mark Okada, both business partners, had a vision. Together, the two men, purchased Protective’s Life’s stake and formed Ranger Assets Management, a company created to assist people with credit strategies, credit hedge funds, and other various accounts. Later that year, the decided to change the company’s name to Highland Financial Management. Since then, Highland Capital has produced some amazing financial feats. In 2000, highland launched its first bank loan fund, that same year, in the year 2000, Highland established a investment 40 Act Platform, in 2004, Highland entered the mutual fund business, and in 20008 and 2011, Highland opened two international offices in Singapore and Seoul.
Today, Highland Capital Management is headquartered in Dallas, TX where they are still trying to find ways to expand their brand. Highland holds a philosophy that their responsibility is to “Produce consistent, above average returns by applying time-tested principles of investing and maintaining discipline around capital preservation while targeting an appropriate risk/return balance in our portfolios. Our focus is on strategies and asset classes where we feel we can add significant value to the investor by either providing unique access to an asset class or unique expertise or skill to the investment process.” Visit hcp.com to know more.
Rodrigo Terpins is your great rally driver of Brazil and more who strives for greatness and loves what he does with great certainty. With a supportive family, especially from his race car driving brother and former successful basketball playing dad, Rodrigo Terpins has the backing needed to become an advantaged rally driver, not only from family support, but from others as well and he definitely appreciates every moment in the rally driving world, from the beginning, of what got him to this success point, until now.
Rodrigo Terpins is currently a fantastic senior director for T5 Partipacoes. There, he has been able to grow the company into a better state, being a huge responsible party in the executions of some of its biggest competitions in Brazil. His efforts has been a huge impact on the company since 2008 and he continues until this day leading and operating as efficient, effective and brilliant as needed for the success of the business for the years to come.
A graduate of Saint Hilaire, his team is always appreciative of his management skills. Claiming that Rodrigo Terpins is one of the better senior directors that they’ve ever had the privilege of experiencing. Well, while we’re on the topic of management skills, prior to working with T5 Partipacoes, well, excuse me, founding T5 Partipacoes, Rodrigo Terpins was the president of Lojas Marisa. Yep, he is an important man that receives much respect, honor and encouragement that keeps his legs moving towards prestigious opportunities.
Well, we won’t credit all of his successes on the support of family and others. No one can deny that Rodrigo is a hard worker who perseveres and has a passion for his job. I mean his dream is rally racing and that’s what he’s a part of. Not only through his driving adventures through rough terrains for competition – and winning awards – but behind the desk as well. Check out Odiario to see more.
Yes I guess you can say that he does it all! What a dream come true for Rodrigo Terpins!
You can search him on Google for more.
The National Coffee Association conducted a very interesting study on coffee in 2009 and 2010. They had discovered that between 2009 and 2010 world coffee production totaled 125.2 million bags, making it the second most-consumed beverage on the planet after water. A recent study was also done on tea by The Tea Association of USA which stated that in the year 2016, tea is the most widely consumed beverage in the world next to water. So, as you can see, both beverage are highly consumed items that we use on a day by day bases to either get through a long day of work or to receive some form of comfort. Visit corpdev.ogmentorship.com to know more.
A fresh cup of coffee is needed to get the juices flowing in the morning. And a nice cup of tea is sometimes essential for relaxation or a good night of sleep. No one offers such high-quality tea and coffee like Organo Gold. Founded in 2008, ORGANO is a global company which operates out of 45 countries on six continents. Organo offers a variety of premium everyday products but they are especially known for their premium coffee and tea. Follow Organo Gold on twitter.com.
Organo has six different types of coffee and three different types of tea. Coffee includes Black Coffee, King of Coffee, Cafe Latte, Cafe Mocha, Cafe Supreme, and Hot Cocoa. Tea includes Green Tea, Red Tea, and Black Ice. Each different type has its own experience. For example, Black Coffee is typically for those who need a kick out of the bed whereas Cafe Latte is more for study. Black Ice tea is for fun in the sun whereas Green Tea is more for a good night rest. No matter the choice, whether it is tea or coffee, you will be satisfied.
The name Clay Siegall might not ring a bell in most people’s minds. Though this guy has done some amazing things for cancer research, he is definitely not a household name. Fortunately, Clay Siegall isn’t trying to be famous, he’s trying to save lives and this is what separates him from the pack. With a Ph.D in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland, this guy has a brilliant educational background. Siegall just so happens to be one of the founders for Seattle Genetics. This Seattle-based biotech company is the worldwide leader in cancer research. It is located in Seattle, Washington, and it specializes in developing and commercializing antibody-based therapies. These are some of the most innovative drugs of all-time.
Siegall is a man of many titles as he’s a doctor, a scientist, a businessman, a mentor and an author. The guy literally has at least 15 patents at the moment. It seems like there isn’t anything that he can’t do when it comes to medical research. Since Seattle Genetics’ inception back in 1998, he has transformed this once tiny startup business into a mega global powerhouse. Siegall spends a lot of time participating in capital-raising activities. These public and private financings have generated up to $1.2 billion. Much of this money goes right back into the business itself, which equals out to a great return on investment.
Targeted therapies are the new norm and Seattle Genetics produces some of the best. They’re far superior than previous cancer fighting medications, and they’re less harsh on the human body. Siegall has helped the company grow in a number of ways. His ability to make multiple strategic licensing deals is one way that he has pushed the envelope. When it’s all said and done, Clay Siegall will go down as one of the most influential figures in the fight against cancer.
Under the leadership of Dr. Clay Siegall at the Seattle Genetics, the group has grown from a mere start-up to a leader in cancer research and treatment. In a recent interview with Inspire, he shares the plans, drug portfolio as well as its position in the 21st-century drug industry.
The Inspiration for Starting the Business
The interest was sparked at the University of Maryland while studying Zoology. It was even compounded the more by the power of technology and his zeal to overcome disease with reason. He quickly learned to the several cancer treatment options like chemotherapy, Seattle Genetics Makes Moneysurgery, and amputation, and that is where he started it all.
How Seattle Genetics Makes Money
The first is from selling their own proprietary drugs, the FDA approved antibodies. They also sell ADCetris. They are also earning from their partnerships for licensing and technological applications, this being despite the fact that 1 out of 10 candidate drugs gets approved by FDA. They started making profits exactly 10 years after getting their IPO.
Seattle Genetics uses referrals to increase their customer base. They also spend time negotiating deals, wining and dining with potential clients. They also have an expert legal team that handles all their technical patenting issues.
The Career of Dr. Siegall at Seattle Genetics
Dr. Clay Siegall was a leading co-founder of the Seattle Genetics in 1998. He serves as its President, Chairman of the Board of Directors and the CEO. The company has built a rich network of antibody-related treatments and cancer therapies. One of their successes in the field is the application of ADCETRIS which was approved by FDA in 2011.
Dr.Siegall has been able to secure more than $750 million through private and public financial sourcing and partnerships. He worked for the Bristol-Myers Squibb Research Institute, 1991-1997. Other international firms that have benefited from this industry include:
- The National Cancer Institute(1988-1991)
- Member of the Board of Directors for the Alder Biopharmaceuticals.
Academics and Professionalism
Dr. Clay Siegall has authored more than 70 publications in cancer treatment and medicine. He owns more than 15 patents. He attended the University of Maryland for his undergraduate studies and proceeded to George Washington University for his Ph.D. in Genetics.
From many news and stories concerning the stock market in America, it is evident that many people are shocked by the fact that more than a third of the American usually invest in Stock. This trend is advancing because more than two-thirds of the people who invest their money in savings accounts are receiving low rates of interests hence making such investors look for other options. Investing in stock market is one of the alternatives they are considering.
The Auto Industry Is About to Completely Change.#AutonomousVehicles #AutonomousCars #Waymo #driverlesscars #technology #ridesharing #banyanhill #Automotive #Automotive $F $GM $FCAUhttps://t.co/zzn3rNnpRd
— Paul Mampilly (@Paul_M_Guru) November 9, 2017
However, one significant factor that is preventing such investors from investing in stock is the primary risks involved in the stock market. Additionally, many people do not have good knowledge about how to invest in stock market. It because of these reasons that Paul Mampilly, an established and experienced financial expert has given some relevant insights to investors who have a desire to know which stock to purchase.
One area that Paul Mampilly encourages the investors to consider is the field of technology and innovation. He says that people who bought stock shares in companies that manufacture cell phones are now enjoying the marvelous profits from the investment. He also foresees that in future most Americans will prefer owning electric automobiles to the previous ancient cars that utilize gasoline as a source of energy.
Another area that investors should consider is the field of medicine. According to Paul, specific medication is a future technological trend. This field entails use genetic testing as a method of accurately diagnosing diseases such as cancer. The genetic profile of the patients will facilitate the doctors to know and understand the personal DNA code of the patient.
Currently, most Americans are eating in their best restaurants more often than before. Due to this many people are more interested in taking healthy meals than before. But the problem is that it is hard for restaurants to cater for consumers that are conscious about health. Food delivery systems that focus on healthy meals are preferred future investments that will solve the problem.
Paul Mampilly has a master’s degree from the University of Fordham explicitly dealing with business administration. After graduating, Paul became an assistant portfolio manager for the Bankers Trust. As he served in this bank, Paul gained more knowledge and skills in investing. As a result, it made him get into higher positions at law firms such as ING and Deutsche Bank. Since then he has gained more than twenty-five years of experience in investing.
About Paul Mampilly: dailyreckoning.com/author/pmampilly/